Latest1 information on COVID-19
©2022 Stanford Medicine
Recruiting
Trial ID: NCT05485207
T3STOPBPS: Open Label Clinical Trial of Transvaginal Trigone Treatment (T3) With Botulinum Toxin A (BTA) for Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Assistant Professor of Urology
Inclusion Criteria:
- Females with IC/BPS
- Females who are considering intradetrusor BTA chemodenervation for the treatment of
refractory IC/BPS
Exclusion Criteria:
- Involvement in other studies with potentially overlapping indications or symptoms
- Patients who are unable to undergo a transvaginal intervention as a result of anatomic
barriers or discomfort will be excluded from enrollment
- patients known to be pregnant or breastfeeding
- Known allergy to BTA injection therapy or lidocaine
drug: Transvaginal botulinum toxin A (BTA) injection
Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amy D. Dobberfuhl, M.D.
650-723-3391